Calypte Only Company with Full Menu of Tests.
Seite 100 von 144 Neuester Beitrag: 03.03.11 19:06 | ||||
| Eröffnet am: | 08.04.05 22:44 | von: Brokersince1. | Anzahl Beiträge: | 4.592 |
| Neuester Beitrag: | 03.03.11 19:06 | von: schubby1 | Leser gesamt: | 220.875 |
| Forum: | Hot-Stocks | Leser heute: | 295 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 97 | 98 | 99 | | 101 | 102 | 103 | ... 144 > | ||||
Change:
+0.04 % Change:
+22.22% High:
0.22 Low:
0.19 Volume:
1,863,300
Price Data Table
Open 0.22
Previous Close 0.22
Exchange of Last Sale CBOE
Time of Last Sale 11:47:25
Tick Unchanged
Bid 0.21
Ask
Size Bid/Ask 1500x1315
Symbol Type Equity
aber immerhin wäre mit einem verbleib an der amex eine vermeintliche kurssicherung um die 0,20$ drin...ohne amex werdet ihr die 0,20$ kaum halten.
sollte die amex wider erwarten gehalten werden, würden mich mal die lügen interessieren, die caly verbreitet hat, um das listing zu halten.
nur DEFINITIVE GROSSE AUFTRÄGE halten auch über wasser, sonst nichts...aber die werden nicht kommen...
für den ein oder anderen bietet sich da heute nochmal eine gute ausstiegschance...
Wenn März keine Aufträge da sind bzw keine Chinazulassung da ist bin ich raus aus Caly.
Bis dahin verbleibe ich mit Hoffnung und guter Dinge.#Lucky
0.22 hiv - CALYPTE BIOMEDICAL CORP
Change:
+0.04 % Change:
+22.22% High:
0.22 Low:
0.19 Volume:
2,283,400
Price Data Table
Open 0.22
Previous Close 0.22
Exchange of Last Sale Pacific
Time of Last Sale 12:07:40
Tick Up
Bid 0.21
Ask
Size Bid/Ask 1500x170
Symbol Type Equity
in meinen augen ist das ding tot und du siehst hier das letzte aufzucken! bleibe drin un spüre es, lucky. vorher glaubst du mir eh nicht!
wenn ganz viele äusserungen fallen, die aktie sei tot,
ist es für mich zeit, einzusteigen.
scheint wohl nun die zeit zu kommen.
und der chart sieht auch sehr gut aus,
beve
einmal vom 02/14/06 und letzte 03/09/06
Beide Handeln doch ( wenn ich richtig verstanden habe ) von einer Aufstockung der Aktienbestandes "CALYPTE BIOMEDICAL CORP filed this Form SC 13G/A"
sehe ich das richtig ???
Kann sehr schlecht Englisch .........;)
Bitte um Antworten
After houer-Handel !
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
resist. 0.28 10
resist. 0.25 8
resist. 0.24 6
resist. 0.22 8
supp 0.21 3
supp 0.20 2
supp 0.20 20
supp 0.19 29
supp 0.18 2
supp 0.18 14
supp 0.17 16
supp 0.16 46
0.21 2300 NLS 17:26:07
0.21 500 NLS 17:26:07
0.22 38000 PAC 17:16:53
0.22 1000 AMX 16:00:22
0.22 1000 AMX 15:59:23
0.22 8500 AMX 15:59:02
0.22 100 NLS 15:58:27
0.22 4700 NLS 15:58:25
0.22 2500 NLS 15:57:53
0.22 12100 NLS 15:57:53
0.23 100 NLS 15:57:53
0.23 100 NLS 15:57:53
0.23 100 NLS 15:57:53
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
0.23 100 NLS 15:57:52
Insider ? denke ich !!
Wo gehts hin heut?
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
LAKE OSWEGO, Ore., March 24 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) announced today that it has received a letter from the American Stock Exchange (the "Amex") regarding the results of the March 13, 2006 hearing conducted before a listing qualifications panel of the Amex Committee on Securities (the "Panel").
The Panel unanimously agreed that the Amex should not move to delist Calypte's common stock at this time and that it would allow the Company until July 31, 2006 to regain compliance with the Amex's continued listing standards. By that date, Calypte must demonstrate that it has regained compliance with the Amex's continued listing standards. If Calypte cannot demonstrate at that time that it is in compliance with those standards, the Panel agreed that the Amex should immediately move to delist Calypte's common stock.
The Company intends to focus on executing its business plan during this time and building stockholder value. However, there can be no assurance that the Company will be able to meet the continued listing standards required to retain the listing of its common stock on the Amex.
Mr. Roger Gale, Chairman and Chief Executive Officer said, "We are grateful that the Amex Panel understood the importance of the coming months and has allowed us additional time to regain compliance with the Amex's listing standards. We believe that the events in the coming quarter will allow us to do so."
About Calypte Biomedical:
Calypte Biomedical Corporation is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Company Contact:
Theodore R Gwin, Chief Financial Officer
(971) 204-0282
email: tgwin@calypte.com
Investor Relations Contact:
Tim Clemensen,
Rubenstein Investor Relations
Phone: (212) 843 9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
Habe mal zu 0,19 gerade gekauft, mal sehen was heute geht.
Grüße, ZN
Grüße, ZN